soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Ongoing #GLP1 -RA Trials soul trial oral semaglutide cardiovascular

The discontinuation rate in clinical trials ranged between 20% and 50% within the first year, with GI intolerance being the primary reason

Semaglutide and Tirzepatide are GLP-1 receptor agonists available in NYC that aid in weight loss by enhancing feelings of fullness, reducing appetite, and improving metabolic function

Gastrointestinal side effects such as diarrhoea may be more pronounced in post-cholecystectomy patients due to altered bile flow and fat digestion patterns

Chad Larson provides nutrition guidance and regular check-ins so the medication works alongside your daily habits rather than as a stand-alone solution